Literature DB >> 20441468

Molecular diagnostics: between chips and customized medicine.

Giuseppe Castaldo1, Francesca Lembo, Rossella Tomaiuolo.   

Abstract

Recently there has been an explosive increase in molecular diagnostics. This is due to translational research on the molecular basis of human diseases, and to technological developments that have resulted in efficient procedures for extensive analysis of the human genome. However, a large body of data on the genome is still difficult to interpret at the clinical level. For many monogenic diseases, "modifier" genes, inherited independently of the disease gene interact, thereby resulting in a distinct phenotype for each patient. Multigenic diseases depend on complex interactions between genes and the environment. Response to drugs and side effects are modulated by gene variants. The same is true for the response to nutrients. All these interactions, which vary from patient to patient, led to the concept of "personalized medicine". Our genome consists of 25,000 genes, a surprisingly low number when compared to other species. Therefore, the complex phenotype of humans depends on a number of mechanisms that regulate gene expression, which, in turn, may be altered resulting in disease. For example, DNA methylation modulates the level of gene expression, and altered methylation of some genes is related to human neoplasias. MicroRNAs regulate the expression of a myriad of genes, and mounting evidence indicates that this mechanism may be impaired in human diseases. Finally, the relationships between genetics and human behavior are starting to be elucidated. For example, suicide may be related to alterations of methylation of specific genes. To conclude: the chip-wide analysis of human genomes is becoming easier, but the understanding of molecular genetics that confirmed the real "uniqueness" of each genome is an excellent opportunity for laboratory medicine to reposition the patient at the heart of the medical process.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20441468     DOI: 10.1515/CCLM.2010.182

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  8 in total

1.  A novel DHPLC-based procedure for the analysis of COL1A1 and COL1A2 mutations in osteogenesis imperfecta.

Authors:  Antonella Fuccio; Mariangela Iorio; Felice Amato; Ausilia Elce; Rosaria Ingino; Mirella Filocamo; Giuseppe Castaldo; Francesco Salvatore; Rossella Tomaiuolo
Journal:  J Mol Diagn       Date:  2011-08-30       Impact factor: 5.568

Review 2.  Congenital diarrhoeal disorders: advances in this evolving web of inherited enteropathies.

Authors:  Roberto Berni Canani; Giuseppe Castaldo; Rosa Bacchetta; Martín G Martín; Olivier Goulet
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-17       Impact factor: 73.082

Review 3.  Congenital diarrheal disorders: an updated diagnostic approach.

Authors:  Gianluca Terrin; Rossella Tomaiuolo; Annalisa Passariello; Ausilia Elce; Felice Amato; Margherita Di Costanzo; Giuseppe Castaldo; Roberto Berni Canani
Journal:  Int J Mol Sci       Date:  2012-03-29       Impact factor: 6.208

Review 4.  Genetic diseases that predispose to early liver cirrhosis.

Authors:  Manuela Scorza; Ausilia Elce; Federica Zarrilli; Renato Liguori; Felice Amato; Giuseppe Castaldo
Journal:  Int J Hepatol       Date:  2014-07-14

5.  An "ex vivo model" contributing to the diagnosis and evaluation of new drugs in cystic fibrosis.

Authors:  A M Di Lullo; M Scorza; F Amato; M Comegna; V Raia; L Maiuri; G Ilardi; E Cantone; G Castaldo; M Iengo
Journal:  Acta Otorhinolaryngol Ital       Date:  2017-06       Impact factor: 2.124

6.  Gene mutation in microRNA target sites of CFTR gene: a novel pathogenetic mechanism in cystic fibrosis?

Authors:  Felice Amato; Manuela Seia; Sonia Giordano; Ausilia Elce; Federica Zarrilli; Giuseppe Castaldo; Rossella Tomaiuolo
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

Review 7.  An update on laboratory diagnosis of liver inherited diseases.

Authors:  Federica Zarrilli; Ausilia Elce; Manuela Scorza; Sonia Giordano; Felice Amato; Giuseppe Castaldo
Journal:  Biomed Res Int       Date:  2013-10-08       Impact factor: 3.411

8.  Exploitation of a very small peptide nucleic acid as a new inhibitor of miR-509-3p involved in the regulation of cystic fibrosis disease-gene expression.

Authors:  Felice Amato; Rossella Tomaiuolo; Fabrizia Nici; Nicola Borbone; Ausilia Elce; Bruno Catalanotti; Stefano D'Errico; Carmine Marco Morgillo; Giuseppe De Rosa; Laura Mayol; Gennaro Piccialli; Giorgia Oliviero; Giuseppe Castaldo
Journal:  Biomed Res Int       Date:  2014-04-15       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.